XML 57 R42.htm IDEA: XBRL DOCUMENT v3.20.4
Collaborations with Third Parties (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Apr. 17, 2020
Jan. 02, 2019
Dec. 31, 2020
Jun. 30, 2020
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Collaborations with Third Parties                              
Revenue         $ 9,638 $ 3,833 $ 212,236 $ 1,840 $ 982 $ 981 $ 982 $ 145,419 $ 227,547 $ 148,364 $ 0
License for Intellectual Property                              
Collaborations with Third Parties                              
Revenue                           144,400  
Ongoing Regulatory and Development Activities                              
Collaborations with Third Parties                              
Revenue                         1,600 4,000  
Regulatory Performance Obligations                              
Collaborations with Third Parties                              
Upfront payment                 1,600         1,600  
Collaboration Revenue                              
Collaborations with Third Parties                              
Revenue         $ 1,471 $ 502 $ 211,627 $ 982 $ 982 $ 981 $ 982 $ 145,419 214,582 $ 148,364 $ 0
Daiichi Sankyo Europe GmbH ("DSE") | NUSTENDI, MAA                              
Collaborations with Third Parties                              
Revenue                         150,000    
Daiichi Sankyo Europe GmbH ("DSE") | NILEMDO and NUSTENDI, sales of bulk tablets                              
Collaborations with Third Parties                              
Revenue                         2,800    
Collaborative Arrangement | Daiichi Sankyo Europe GmbH ("DSE")                              
Collaborations with Third Parties                              
Upfront cash payment   $ 150,000                          
Cash payment to the Company upon first commercial sales in the DSE Territory   $ 150,000                          
Collaborative Arrangement | Daiichi Sankyo Europe GmbH ("DSE") | Minimum                              
Collaborations with Third Parties                              
Percentage of royalties to be received on the net sales   15.00%                          
Collaborative Arrangement | Daiichi Sankyo Europe GmbH ("DSE") | Maximum                              
Collaborations with Third Parties                              
Percentage of royalties to be received on the net sales   25.00%                          
Collaborative Arrangement | Serometrix [Member]                              
Collaborations with Third Parties                              
Upfront cash payment     $ 12,500                        
Amended License And Collaboration Agreement | Daiichi Sankyo Europe GmbH ("DSE")                              
Collaborations with Third Parties                              
Proceeds received upon completion of NUSTENDI MAA transfer       $ 150,000                      
Exclusive Development And Commercialization Rights To Nexletol And Nexlizet Tablets | Otsuka Pharmaceutical Co Ltd                              
Collaborations with Third Parties                              
Upfront cash payment $ 60,000                            
Potential additional future payments $ 450,000                            
Exclusive Development And Commercialization Rights To Nexletol And Nexlizet Tablets | Otsuka Pharmaceutical Co Ltd | Minimum                              
Collaborations with Third Parties                              
Percentage of royalties to be received on the net sales 15.00%                            
Exclusive Development And Commercialization Rights To Nexletol And Nexlizet Tablets | Otsuka Pharmaceutical Co Ltd | Maximum                              
Collaborations with Third Parties                              
Percentage of royalties to be received on the net sales 30.00%                            
Milestone payment, first JNDA submissions $ 20,000                            
Milestone payment, first NHI Price Listing for NEXLETOL in the Otsuka Territory 70,000                            
Milestone payment, achievement of the primary MACE in the CLEAR Outcomes study and CV risk reduction rate on the U.S. label 50,000                            
Milestone payments related to total net sales achievements $ 310,000                            
Exclusive Development And Commercialization Rights To Nexletol And Nexlizet Tablets | Otsuka Pharmaceutical Co Ltd | Collaboration Revenue                              
Collaborations with Third Parties                              
Revenue                         $ 60,000